Evidence map›Paper›PMID 39101958›Full record

Trial reportInternational urogynecology journal2024

Posterior Tibial Nerve Stimulation With versus Without Mirabegron: A Randomized Controlled Trial.

Russell F Stanley, Isuzu Meyer, Christina T Blanchard, Holly E Richter

Registry-linked trialAbstract readRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International urogynecology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06438861 (Exploring the Additive Effect of Vibegron to Intradetrusor OnabotulinumtoxinA in Women With Refractory Overactive Bladder), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06438861 nawithdrawnnot on this mapstarted 2025, after this paper: background citation

Exploring the Additive Effect of Vibegron to Intradetrusor OnabotulinumtoxinA in Women With Refractory Overactive Bladder

TypeinterventionalSponsorUniversity of Alabama at BirminghamRan2025 to 2025Enrolled0ConditionsOveractive Bladder SyndromeArmsVibegron 75mg, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Russell F StanleyDivision of Urogynecology and Reconstructive Pelvic Surgery, University of Alabama at Birmingham, Bldg. 176F, Suite10382, 619 19th, Street South, Birmingham, AL, 35249, USA.
Isuzu MeyerDivision of Urogynecology and Reconstructive Pelvic Surgery, University of Alabama at Birmingham, Bldg. 176F, Suite10382, 619 19th, Street South, Birmingham, AL, 35249, USA.
Christina T BlanchardDivision of Urogynecology and Reconstructive Pelvic Surgery, University of Alabama at Birmingham, Bldg. 176F, Suite10382, 619 19th, Street South, Birmingham, AL, 35249, USA.
Holly E RichterDivision of Urogynecology and Reconstructive Pelvic Surgery, University of Alabama at Birmingham, Bldg. 176F, Suite10382, 619 19th, Street South, Birmingham, AL, 35249, USA. hrichter@uabmc.edu.ORCID 0000-0001-7741-5771

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and hypothesisTo compare change in urgency urinary incontinence episodes (UUIEs) in women undergoing posterior tibial nerve stimulation (PTNS) plus mirabegron versus PTNS plus placebo for the treatment of refractory urgency urinary incontinence (UUI). The primary hypothesis was that combination therapy is superior to monotherapy.

methodsA randomized controlled trial was performed in individuals identifying as female aged ≥ 18 years with UUI symptoms refractory to second-line treatment or who could not tolerate antimuscarinic medications. Both participants and providers were blinded to medication treatment allocation. Participants were randomized (1:1) to PTNS plus mirabegron or PTNS plus placebo. Participants completed a 3-day bladder diary prior to and after 12-week treatment. Validated symptom distress and impact questionnaires were obtained pre- and post-treatment. The primary outcome was change in mean number of UUIEs on a 3-day bladder diary pre- versus post-treatment between arms. Primary and secondary outcomes were analyzed via sample t tests.

resultsFifty-four subjects were randomized, mean ± SD baseline age 56.2±15.6 years and body mass index 35.0±9.4 (kg/m

conclusionsIn subjects undergoing PTNS treatment for refractory UUI and OAB-wet symptoms, the addition of a β-3 agonist produced significant improvement in both objective and subjective overactive bladder symptom outcomes compared with PTNS plus placebo.

Indexed as

AcetanilidesThiazolesTibial NerveAdultAgedCombined Modality TherapyDouble-Blind MethodFemaleHumansMiddle AgedTreatment OutcomeUrinary Incontinence, UrgeAcetanilidesmirabegronThiazolesMirabegronNocturiaOveractive bladderPosterior tibial nerve stimulationUrgency urinaryUrinary frequencyUrinary incontinence

Identifiers

PMID39101958
PMCPMC11380641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.